Richard A Preston1, James O Coffey, Barry J Materson, Marlies Ledford, Alberto B Alonso. 1. Division of Clinical Pharmacology Clinical Research Center, Department of Medicine, Leonard M. Miller School of Medicine, University of Miami, Miami, FL 33136, United States. rpreston@med.miami.edu <rpreston@med.miami.edu>
Abstract
BACKGROUND: Uncontrolled severe hypertension is associated with alarming rates of cardiovascular events but the mechanisms of vascular injury are not well understood. Recent investigative interest has focused on platelet activation and platelet P-selectin (CD62P) as direct mediators of vascular inflammation and injury. We investigated the association of extreme blood pressure (BP) elevation with platelet P-selectin and fibrinolytic markers in high risk patients with severe hypertension. METHODS: Cross-sectional comparison of platelet CD62, tissue plasminogen activator antigen (tPA), and plasminogen activator inhibitor-1 activity (PAI-1) among 3 BP groups: untreated severely hypertensive patients (SHT; n=18), untreated mildly hypertensive patients (MHT; n=19), and normotensive controls (NT; n=16). RESULTS: Platelet CD62 was greatest in SHT (p=0.00008) and showed a strong correlation with both systolic (p=0.0002, r=0.52) and diastolic (p=0.0003, r=0.52) BP. tPA was greater in SHT than MHT or NT (ANOVA; p=0.02) and correlated with diastolic BP but not SBP. PAI-1 did not correlate with either SBP or DBP but was related to body mass index, diabetes, and dyslipidemia. CONCLUSIONS: Platelet CD62 demonstrated a strong and graded association with both systolic and diastolic BP that persisted in the presence of multiple concomitant risk factors. The association of BP with CD62P was stronger than with either PAI-1 or tPA-Ag. Platelet activation and platelet CD62 increase in a BP-dependent manner and this relationship persists at extreme levels of BP. Platelet activation and platelet CD62 may participate in the accelerated target organ injury observed in high risk patients with severe hypertension.
BACKGROUND: Uncontrolled severe hypertension is associated with alarming rates of cardiovascular events but the mechanisms of vascular injury are not well understood. Recent investigative interest has focused on platelet activation and platelet P-selectin (CD62P) as direct mediators of vascular inflammation and injury. We investigated the association of extreme blood pressure (BP) elevation with platelet P-selectin and fibrinolytic markers in high risk patients with severe hypertension. METHODS: Cross-sectional comparison of platelet CD62, tissue plasminogen activator antigen (tPA), and plasminogen activator inhibitor-1 activity (PAI-1) among 3 BP groups: untreated severely hypertensivepatients (SHT; n=18), untreated mildly hypertensivepatients (MHT; n=19), and normotensive controls (NT; n=16). RESULTS: Platelet CD62 was greatest in SHT (p=0.00008) and showed a strong correlation with both systolic (p=0.0002, r=0.52) and diastolic (p=0.0003, r=0.52) BP. tPA was greater in SHT than MHT or NT (ANOVA; p=0.02) and correlated with diastolic BP but not SBP. PAI-1 did not correlate with either SBP or DBP but was related to body mass index, diabetes, and dyslipidemia. CONCLUSIONS: Platelet CD62 demonstrated a strong and graded association with both systolic and diastolic BP that persisted in the presence of multiple concomitant risk factors. The association of BP with CD62P was stronger than with either PAI-1 or tPA-Ag. Platelet activation and platelet CD62 increase in a BP-dependent manner and this relationship persists at extreme levels of BP. Platelet activation and platelet CD62 may participate in the accelerated target organ injury observed in high risk patients with severe hypertension.
Authors: Peter Kochunov; David Glahn; Jack Lancaster; Anderson Winkler; Jack W Kent; Rene L Olvera; Shelley A Cole; Thomas D Dyer; Laura Almasy; Ravi Duggirala; Peter T Fox; John Blangero Journal: Stroke Date: 2010-08-19 Impact factor: 7.914
Authors: Suzette J Bielinski; Cecilia Berardi; Paul A Decker; Phillip S Kirsch; Nicholas B Larson; James S Pankow; Michele Sale; Mariza de Andrade; Hugues Sicotte; Weihong Tang; Naomi Q Hanson; Christina L Wassel; Joseph F Polak; Michael Y Tsai Journal: Atherosclerosis Date: 2015-02-23 Impact factor: 5.162
Authors: Armen Yuri Gasparyan; Antonios Stavropoulos-Kalinoglou; Dimitri P Mikhailidis; Karen M J Douglas; George D Kitas Journal: Rheumatol Int Date: 2011-02 Impact factor: 2.631
Authors: Peter Kochunov; David C Glahn; Jack Lancaster; Anderson Winkler; Kathrin Karlsgodt; Rene L Olvera; Joanna E Curran; Melanie A Carless; Thomas D Dyer; Laura Almasy; Ravi Duggirala; Peter T Fox; John Blangero Journal: Hypertension Date: 2010-12-06 Impact factor: 10.190
Authors: P Kochunov; D C Glahn; L E Hong; J Lancaster; J E Curran; M P Johnson; A M Winkler; H H Holcomb; J W Kent; B Mitchell; V Kochunov; R L Olvera; S A Cole; T D Dyer; E K Moses; H Goring; L Almasy; R Duggirala; J Blangero Journal: Front Genet Date: 2012-05-01 Impact factor: 4.599
Authors: Jan K Nowak; Irena Wojsyk-Banaszak; Edyta Mądry; Andrzej Wykrętowicz; Patrycja Krzyżanowska; Sławomira Drzymała-Czyż; Agata Nowicka; Andrzej Pogorzelski; Ewa Sapiejka; Wojciech Skorupa; Mariusz Szczepanik; Aleksandra Lisowska; Jaroslaw Walkowiak Journal: Lung Date: 2017-06-23 Impact factor: 2.584